SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation S9346A

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy

RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin.

NCT01120262 Prostate Cancer Genetic: gene expression analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis
MeSH: Prostatic Neoplasms
HPO: Prostate cancer Prostate neoplasm

S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. --- S9346A ---

Primary Outcomes

Measure: Serum PSA values at 7 months

Time: 7 months

Measure: Role of genetic variation in response to therapy

Time: baseline


HPO Nodes


Prostate cancer
Genes 32
RNASEL TP53 RNF43 PTEN BARD1 RAD50 BRCA2 NBN BMPR1A BRCA1 NAB2 CDH1 RAD51C MXI1 PALB2 EPHB2 CHEK2 BRCA2 BRIP1 GREM1 MRE11 CHEK2 RAD51 ZFHX3 MAD1L1 TP53 RAD51D AR STAT6 PTEN APC KLF6